Tag: Ocugen

The investment case for Ocugen is under severe pressure as its stock experiences a dramatic downward spiral. With bearish investors ...

Biotechnology firm Ocugen finds itself at a critical juncture. With its shares under significant pressure, CEO Dr. Shankar Musunuri is ...

Biotechnology firm Ocugen Inc. finds itself navigating a critical juncture. While the company's latest earnings report revealed substantial revenue growth, ...

Biopharmaceutical firm Ocugen finds itself navigating turbulent financial waters as its promising gene therapy pipeline advances through clinical trials. The ...

Ocugen, Inc. witnessed a sharp 7% decline in its share price on Wednesday, a downturn driven by investor apprehension over ...

Biopharmaceutical firm Ocugen presents investors with a classic dilemma: promising clinical developments in gene therapy set against a backdrop of ...

While Ocugen's latest financial results showed continued losses, market participants are focusing squarely on the company's advancing clinical programs. The ...

The biotechnology firm Ocugen finds itself in a pivotal position, balancing promising clinical progress against a rapidly diminishing cash reserve. ...

The financial outlook for Ocugen has grown increasingly precarious, with the biotechnology firm's stock extending losses for five consecutive trading ...

Ocugen's latest quarterly earnings report has triggered alarm bells across the investment community. The clinical-stage biopharmaceutical company reported a significantly ...